Latest filing published 09 Jun 2023 for NEXGEL, INC., €2,059.
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 12 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -20.3%Entry US$54.20 · Close at T+365 US$43.20
- -11.2%Entry US$48.20 · Close at T+365 US$42.80
- +46.9%Entry US$28.60 · Close at T+365 US$42.00
- +44.6%Entry US$31.20 · Close at T+365 US$45.10
- +41.6%Entry US$35.60 · Close at T+365 US$50.40
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
David Stefansky: trading record in brief
David Stefansky (board member) discloses dealings in 2 companies, chiefly Nexgel, Inc. and Alliqua BioMedical, Inc. We count 13 filings; the first trade dates from 6 January 2014 and the latest from 8 June 2023.
Purchases make up the whole of the open-market record (12 purchases, €116k). Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 1 share grant. Since January 2023: 4 purchases and no sales on the market.
The median purchase comes to €6,445. Clusters matter here: 9 out of 12 purchases overlapped with buying by a colleague within 30 days. Purchases made close together by different insiders form what is called a cluster. For 12 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 25% of cases, with a median move of -14.6%. Past outcomes like these are no guarantee of what comes next.
Most recently, on 9 June 2023, the filings show an open-market purchase worth €2,059 in Nexgel, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to David Stefansky
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 1,000 shares@ US$2.221.8% of flowCommon StockSEC:0001493152-23-020659:1Canonical exit: 6 Sept 2023 (T+90)
- 2,000 shares@ US$2.504.4% of flowCommon StockSEC:0001493152-23-020659:0Canonical exit: 5 Sept 2023 (T+90)
- 2,000 shares@ US$2.423.9% of flowCommon StockSEC:0001493152-23-019751:1Canonical exit: 29 Aug 2023 (T+90)
- 5,000 shares@ US$2.5311.2% of flowCommon StockSEC:0001493152-23-019751:0Canonical exit: 28 Aug 2023 (T+90)
- 5,000 shares@ US$1.597.1% of flowCommon StockSEC:0001493152-22-035878:0Canonical exit: 19 Mar 2023 (T+90)
- 7,500 shares@ US$1.44339.8% of flowCommon StockSEC:0001493152-22-035308:0Canonical exit: 12 Mar 2023 (T+90)
- 5,000 shares@ US$1.6567.8% of flowCommon StockSEC:0001493152-22-024446:0Canonical exit: 28 Nov 2022 (T+90)
- 5,000 shares@ US$1.738.2% of flowCommon StockSEC:0001493152-22-024116:0Canonical exit: 23 Nov 2022 (T+90)
- 2,500 shares@ US$1.793.8% of flowCommon StockSEC:0001493152-22-023279:1Canonical exit: 14 Nov 2022 (T+90)
- 2,872 shares@ US$1.90335.1% of flowCommon StockSEC:0001493152-22-023279:0Canonical exit: 13 Nov 2022 (T+90)
- 3,128 shares@ US$1.59624.5% of flowCommon StockSEC:0001493152-22-017807:0Canonical exit: 22 Sept 2022 (T+90)
- 9,091 shares@ US$5.4941.8% of flowCommon StockSEC:0001104659-22-000433:0Canonical exit: 27 Mar 2022 (T+90)
- 194,667 sharesCommon StockSEC:0001144204-14-001299:0
13 of 13 declarations